Cochlear Shares Building Momentum, Up 28% In Two Months: The Latest

Cochlear shares (ASX: COH) climbed 2.6% to A$121.08 on Monday, touching a session high of A$121.14 and pushing into overbought territory as investors continued to back a quality healthcare rebound narrative despite lingering uncertainty over near-term earnings delivery. The rally extends a recovery that has lifted the stock 28% since the end of April, with the recent momentum pushing the Cochlear share price back above A$120, having found resistance in the past weeks.

The near term momentum is also supported by the 30 day SMA meeting and pushing above the 50 SMA on the daily. The approach to overbought on the RSI makes a sharp shift for Cochlear shares, one of the most heavily oversold names on the ASX in mid April with an RSI of 10.

Cochlear stock sentiment improves

The move appears to reflect a shift in investor focus from macro headwinds and operational stumbles toward the medium-term promise of the Nucleus Nexa System, the world’s first smart cochlear implant with upgradeable firmware. With Nexa now rolling out globally and carrying US FDA approval, the market is leaning into a story of volume recovery and services upgrade cycles from late FY26 into FY27, even as near-term challenges in the Middle East, US payer environment, and Western Europe remain unresolved.

That optimism sits in tension with the April reset that slashed FY26 underlying net profit guidance to A$290-330 million from A$435-460 million, triggering a 41% one-day share price collapse and resetting expectations around growth and margins. The downgrade, driven by Middle East conflict disrupting budgets and procurement, US Medicare Advantage payer pressure, Western Europe execution issues, and a A$25 million after-tax drag from Australian dollar strength, remains the backdrop for any repair trade. Yet the speed and persistence of the rebound suggest investors are treating those headwinds as transitory and pricing in a return to form once Nexa gains traction and geopolitical noise fades.

The product cycle narrative is central to the bull case. Nexa’s smart implant platform is designed to reinvigorate processor upgrades and drive penetration in emerging markets, with independent research highlighting the system as a key catalyst for reviving implant volumes.

The broader healthcare and medical device sector context also supports the rebound. Cochlear’s issues mirror themes across the sector, including capacity constraints in Europe, US reimbursement pressure, and China reimbursement changes.

A constructive tone for ASX healthcare or defensives would reinforce the idea that investors are rotating back into high-quality names that have already been de-rated. Recent analysis suggests Middle East sales are delayed rather than lost, US patient volumes remain intact despite payer friction, and Western Europe weakness is mainly execution-related and fixable. That framing helps Cochlear look like a relatively clean way to play a medium-term recovery in elective and semi-elective procedures, with reimbursement friction treated as a macro drag that will eventually normalise.

View From The Street

Consensus 12-month price targets sit around A$127, roughly 5% above Monday’s close, signalling the Street is modestly constructive but not aggressively bullish. Recent broker commentary clusters around Hold or Neutral ratings, with key houses emphasising near-term headwinds and execution risk even as they acknowledge the wide moat and long-term runway.

Today’s strength thus slightly front-runs the Street: the price is drifting toward or beyond several fair-value markers before evidence of sustained volume recovery, setting up a tension between market momentum and cautious analyst models. The Street is not chasing Cochlear aggressively, and the current rally reflects retail and institutional positioning rather than a wave of broker upgrades.

Technical Read

Cochlear’s 14-period RSI has climbed to 70, into overbought territory, consistent with a short-term momentum extension rather than a basing pattern. Technically, Cochlear is in a near-term momentum squeeze off its decade lows, with bargain hunters keen to step in at depressed levels. There are also the makings of a cup and handle pattern on the chart, with the A$120 level the neckline to break.

The recent rally from A$88.74 to above A$120 means part of the deep value argument has been eroded. With the stock now above or around key bearish and neutral markers, the risk-reward is more finely balanced if FY26-27 delivery disappoints. Investors are effectively backing a Nexa-led earnings repair story despite still-cloudy guidance and recent downgrades, making the next set of volume and margin updates critical to validating the current momentum.